Literature DB >> 24252804

The role of oxidative stress in Parkinson's disease.

Vera Dias1, Eunsung Junn, M Maral Mouradian.   

Abstract

Oxidative stress plays an important role in the degeneration of dopaminergic neurons in Parkinson's disease (PD). Disruptions in the physiologic maintenance of the redox potential in neurons interfere with several biological processes, ultimately leading to cell death. Evidence has been developed for oxidative and nitrative damage to key cellular components in the PD substantia nigra. A number of sources and mechanisms for the generation of reactive oxygen species (ROS) are recognized including the metabolism of dopamine itself, mitochondrial dysfunction, iron, neuroinflammatory cells, calcium, and aging. PD causing gene products including DJ-1, PINK1, parkin, alpha-synuclein and LRRK2 also impact in complex ways mitochondrial function leading to exacerbation of ROS generation and susceptibility to oxidative stress. Additionally, cellular homeostatic processes including the ubiquitin-proteasome system and mitophagy are impacted by oxidative stress. It is apparent that the interplay between these various mechanisms contributes to neurodegeneration in PD as a feed forward scenario where primary insults lead to oxidative stress, which damages key cellular pathogenetic proteins that in turn cause more ROS production. Animal models of PD have yielded some insights into the molecular pathways of neuronal degeneration and highlighted previously unknown mechanisms by which oxidative stress contributes to PD. However, therapeutic attempts to target the general state of oxidative stress in clinical trials have failed to demonstrate an impact on disease progression. Recent knowledge gained about the specific mechanisms related to PD gene products that modulate ROS production and the response of neurons to stress may provide targeted new approaches towards neuroprotection.

Entities:  

Keywords:  Neurodegeneration; dopamine; mitochondria; neuroinflammation; neuroprotection; reactive oxygen species

Mesh:

Substances:

Year:  2013        PMID: 24252804      PMCID: PMC4135313          DOI: 10.3233/JPD-130230

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  451 in total

1.  Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins.

Authors:  Dong-Hoon Hyun; MoonHee Lee; Barry Halliwell; Peter Jenner
Journal:  J Neurochem       Date:  2003-07       Impact factor: 5.372

2.  Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates.

Authors:  Chunjuan Huang; Han Cheng; Shufeng Hao; Hui Zhou; Xujia Zhang; Jianen Gao; Qi-Hong Sun; Hongyu Hu; Chih-Chen Wang
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

3.  Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy.

Authors:  Vinay Choubey; Dzhamilja Safiulina; Annika Vaarmann; Michal Cagalinec; Przemyslaw Wareski; Malle Kuum; Alexander Zharkovsky; Allen Kaasik
Journal:  J Biol Chem       Date:  2011-01-20       Impact factor: 5.157

4.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

5.  Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.

Authors:  J P Spencer; P Jenner; S E Daniel; A J Lees; D C Marsden; B Halliwell
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

6.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

7.  Quantifying the global cellular thiol-disulfide status.

Authors:  Rosa E Hansen; Doris Roth; Jakob R Winther
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

8.  Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein.

Authors:  Wei Zhang; Shannon Dallas; Dan Zhang; Jian-Ping Guo; Hao Pang; Belinda Wilson; David S Miller; Biao Chen; Wanqin Zhang; Patrick L McGeer; Jau-Shyong Hong; Jing Zhang
Journal:  Glia       Date:  2007-08-15       Impact factor: 7.452

9.  Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.

Authors:  Matthias Elstner; Sarina K Müller; Lars Leidolt; Christoph Laub; Lena Krieg; Falk Schlaudraff; Birgit Liss; Chris Morris; Douglass M Turnbull; Eliezer Masliah; Holger Prokisch; Thomas Klopstock; Andreas Bender
Journal:  Mol Brain       Date:  2011-12-21       Impact factor: 4.041

10.  Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.

Authors:  Vanessa A Morais; Patrik Verstreken; Anne Roethig; Joél Smet; An Snellinx; Mieke Vanbrabant; Dominik Haddad; Christian Frezza; Wim Mandemakers; Daniela Vogt-Weisenhorn; Rudy Van Coster; Wolfgang Wurst; Luca Scorrano; Bart De Strooper
Journal:  EMBO Mol Med       Date:  2009-05       Impact factor: 12.137

View more
  449 in total

Review 1.  Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.

Authors:  Mohammed Akbar; Musthafa Mohamed Essa; Ghazi Daradkeh; Mohamed A Abdelmegeed; Youngshim Choi; Lubna Mahmood; Byoung-Joon Song
Journal:  Brain Res       Date:  2016-02-13       Impact factor: 3.252

Review 2.  Long Non-coding RNAs in Parkinson's Disease.

Authors:  Chengqi Xin; Jing Liu
Journal:  Neurochem Res       Date:  2021-02-05       Impact factor: 3.996

Review 3.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

Review 4.  Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Maria Nguyen; Yvette C Wong; Daniel Ysselstein; Alex Severino; Dimitri Krainc
Journal:  Trends Neurosci       Date:  2018-11-30       Impact factor: 13.837

5.  The neuroprotective role of ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells.

Authors:  Parijat Kabiraj; Carlos A Valenzuela; Jose E Marin; David A Ramirez; Lois Mendez; Michael S Hwang; Armando Varela-Ramirez; Karine Fenelon; Mahesh Narayan; Rachid Skouta
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

6.  Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide.

Authors:  Alireza Abdanipour; Iraj Jafari Anarkooli; Saeed Shokri; Mehrdad Ghorbanlou; Vahid Bayati; Reza Nejatbakhsh
Journal:  Biomed Rep       Date:  2017-11-22

7.  Telmisartan attenuates hydrogen peroxide-induced apoptosis in differentiated PC12 cells.

Authors:  Guan Tao Du; Xuan Ke; Guo Liang Meng; Guang Jun Liu; Hui Ying Wu; Jin Hong Gong; Xiao Dan Qian; Jin Luo Cheng; Hao Hong
Journal:  Metab Brain Dis       Date:  2018-05-03       Impact factor: 3.584

8.  Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes.

Authors:  Matthew Neal; Jie Luo; Dilshan S Harischandra; Richard Gordon; Souvarish Sarkar; Huajun Jin; Vellareddy Anantharam; Laurent Désaubry; Anumantha Kanthasamy; Arthi Kanthasamy
Journal:  Glia       Date:  2018-09-12       Impact factor: 7.452

9.  Evaluation of Mitochondrial Function and Morphology in Drosophila.

Authors:  Yinglu Tang; Foozhan Tahmasebinia; Zhihao Wu
Journal:  Methods Mol Biol       Date:  2021

Review 10.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.